DUBLIN–(BUSINESS WIRE)–The “Ophthalmic Lasers – Global Market Trajectory & Analytics” report has been added to ResearchAndMarkets.com’s offering. Global Ophthalmic Lasers Market to Reach $1.7 Billion by 2027 Amid the COVID-19 crisis, the global m…
Author: Business Wire
United States Dry Eye Markets and Competitive Landscape Report 2022: Pipeline, Epidemiology, Valuations and Forecasts, Sales and Competitive Landscape – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “US Dry Eye Market and Competitive Landscape – 2022” report has been added to ResearchAndMarkets.com’s offering. US Dry Eye Market and Competitive Landscape Report provides comprehensive insights into Dry Eye pipeline produ…
EnChroma startet den internationalen Monat zur Sensibilisierung für Farbenblindheit
BERKELEY, Kalifornien–(BUSINESS WIRE)– #enchroma–EnChroma, Inc. – Entwickler von Brillen für Farbenblindheit – gab heute den Start des Internationalen Monats zur Sensibilisierung für Farbenblindheit bekannt. Während des gesamten Monats September wer…
Samenvatting: EnChroma lanceert International Color Blindness Awareness Month
BERKELEY, Californië–(BUSINESS WIRE)–EnChroma, Inc. – makers van brillen voor kleurenblindheid – heeft vandaag de lancering aangekondigd van de International Color Blindness Awareness Month. Gedurende de hele maand september zullen EnChroma en meer d…
Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PARSIPPANY, N.J.–(BUSINESS WIRE)–Iveric Bio granted equity-based awards pursuant to the Company’s 2019 Inducement Stock Incentive Plan to two newly-hired, non-executive employees.
Resumen: EnChroma lanza el Mes Internacional de Concienciación sobre el Daltonismo
BERKELEY, California–(BUSINESS WIRE)–EnChroma, Inc. -creadores de gafas para el daltonismo- ha anunciado hoy el lanzamiento del Mes Internacional de Concienciación sobre el Daltonismo. Durante todo el mes de septiembre, EnChroma y más de 50 museos, b…
EnChroma lance le mois international de la sensibilisation au daltonisme
BERKELEY, Californie–(BUSINESS WIRE)–EnChroma, Inc. – le créateur de lunette pour daltoniens – annonce aujourd’hui le lancement du mois international de sensibilisation au daltonisme. Durant tout le mois de septembre, EnChroma et plus de 50 musées, b…
Riassunto: EnChroma lancia l'International Color Blindness Awareness Month (Mese internazionale di sensibilizzazione sul daltonismo)
BERKELEY, Calif.–(BUSINESS WIRE)–EnChroma, Inc. – creatori di occhiali per il daltonismo – ha annunciato oggi il lancio dell’ International Color Blindness Awareness Month. Per tutto il mese di settembre, EnChroma e oltre 50 musei, biblioteche, distr…
German Federal Ministry of Education and Research awards grants to fund a clinical trial for LISA Laser innovated “novel treatment of urolithiasis”
GÖTTINGEN, Germany–(BUSINESS WIRE)–On the 26th of August 2022, the German Federal Ministry of Education and Research selected a “novel approach for the treatment of urolithiasis” for funding (Grant No. 13GW0628). Urolithiasis (urinary stone formation…
EnChroma Launches International Color Blindness Awareness Month
BERKELEY, Calif.–(BUSINESS WIRE)– #enchroma–EnChroma Launches International Color Blindness Awareness Month; 50+ Organizations to Generate Awareness for Prevalence & Effects of Color Blindness
RudderStack Announces HIPAA-Compliant Customer Data Solution
SAN FRANCISCO–(BUSINESS WIRE)–RudderStack today announced HIPAA compliance, giving healthcare companies an easier way to manage and protect customer data. As a compliant solution provider, RudderStack can sign a Business Associate Agreement (BAA) wit…
National Vision Holdings, Inc. Announces Participation in the Goldman Sachs 29th Annual Global Retailing Conference
DULUTH, Ga.–(BUSINESS WIRE)–National Vision Holdings, Inc. (NASDAQ: EYE) today announced that the Company is scheduled to present at the Goldman Sachs 29th Annual Global Retailing Conference on Wednesday, September 7, 2022, at 3:15 p.m. Eastern Time….
Vivani Announces Trading under New Ticker Symbol (Nasdaq: VANI)
EMERYVILLE, Calif.–(BUSINESS WIRE)–Vivani Medical, Inc., formerly Second Sight Medical, Inc., (NASDAQ: VANI) (the “Company” or “Vivani”) announced that trading of the Company’s common stock on The Nasdaq Capital Market under the symbol “VANI” will co…
Isarna Therapeutics Presents Update from Phase 2 BETTER Clinical Study in Wet AMD and DME at the EURETINA Meeting
MUNICH–(BUSINESS WIRE)–Isarna Therapeutics will present an update from its ISTH0036 clinical development program and the ongoing BETTER Study at the EURETINA meeting in Hamburg, Germany on September 1st, 2022. Prof. Marion Munk, MD, PhD, FEBO, the CM…
Meredith Ryan-Reid Named CEO of Versant Health, a MetLife Company
NEW YORK–(BUSINESS WIRE)–MetLife announced that Meredith Ryan-Reid has been named CEO of Versant Health, a managed vision care company and wholly-owned subsidiary of MetLife.
OKYO Pharma Plans Q4 2022 IND Filing of OK-101 to treat Dry Eye Disease with Subsequent Phase 2 Initiation Alongside Peptide Manufacturing Partner, AmbioPharm
LONDON & NEW YORK & NORTH AUGUSTA, S.C.–(BUSINESS WIRE)– #DryEye–OKYO Pharma Limited (NASDAQ: OKYO; LSE: OKYO), a biotechnology company focused on the discovery and development of novel molecules to treat inflammatory dry eye diseases and ocular pai…
Second Sight Medical Products Announces Successful Completion of its Merger with Nano Precision Medical and its Name Change to Vivani Medical, Inc.
LOS ANGELES–(BUSINESS WIRE)–Second Sight Medical Products, Inc.(NASDAQ: EYES) (the “Company” or “Second Sight”), a leading developer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individua…
Europe Ophthalmic Drug Delivery System Market to Grow at 6.4% Through 2031 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Europe Ophthalmic Drug Delivery System Market 2021-2031 by Product, Dosage Form, Disease, Setting, and Country: Trend Forecast and Growth Opportunity” report has been added to ResearchAndMarkets.com’s offering. Europe opht…
Resumen: La Comisión Europea concede la autorización de comercialización de Ranivisio▼®* (ranibizumab), un biosimilar de Lucentis®**, para la degeneración macular asociada a la edad (DMAE), la causa más común de ceguera en los países desarrollados
TEL AVIV, Israel–(BUSINESS WIRE)–Teva Pharmaceutical Industries Ltd. ha anunciado que la Comisión Europea (CE) ha concedido una autorización de comercialización para Ranivisio (ranibizumab), un biosimilar del tratamiento oftalmológico Lucentis en las…
La Commission européenne accorde une autorisation de mise sur le marché à Ranivisio▼®* (ranibizumab), un biosimilaire du Lucentis®**, pour le traitement de la dégénérescence maculaire liée à l'âge (DMLA), cause la plus fréquente de cécité dans les…
TEL AVIV, Israël–(BUSINESS WIRE)– La Commission européenne accorde une autorisation de mise sur le marché à Ranivisio▼®* (ranibizumab), un biosimilaire du Lucentis®**, pour le traitement de la dégénérescence maculaire liée à l’âge (DMLA), cause la p…